Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ergotamine Drugs Are Latest Target In FDA Crackdown On Unapproved Medications

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA warns eight manufacturers and 12 distributors to stop marketing unapproved drugs that contain ergotamine tartrate.

You may also be interested in...



FDA Announces Withdrawal Of Unapproved Suppository Drugs For Nausea/Vomiting

Agency also is revoking NDA approval of King’s Tigan trimethobenzamide suppositories.

FDA Announces Withdrawal Of Unapproved Suppository Drugs For Nausea/Vomiting

Agency also is revoking NDA approval of King’s Tigan trimethobenzamide suppositories.

FDA Calls For Third-Party Auditor To Rectify Actavis Manufacturing Problems

Icelandic generics firm has received two warning letters concerning its New Jersey manufacturing plant.

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel